News, $GNCA 5.05 0.00 0.00 193,938 5.41 5.47
Genocea Biosciences Files 8K - Regulation FD >GNCA
1 hour 45 minutes ago - DJNF
Genocea Biosciences Inc. (GNCA) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on July 24, 2017.
On July 24, 2017, Genocea Biosciences, Inc. (the "Company"
issued a press release announcing positive clinical results from the Company's planned analysis of data collected twelve months after dosing in its placebo-controlled Phase 2b trial of GEN-003 for the treatment of genital herpes. A copy of the press release, dated July 24, 2017, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
On July 24, 2017, the Company will give a presentation to investors regarding the positive clinical results for the twelve-month analysis of the Company's Phase 2b trial of GEN-003 for the treatment of genital herpes. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference. The presentation is also available on the Company's website, www.genocea.com, however the Company's website and any information contained on the website are not incorporated herein.
The information contained in this Item 7.01 of this Current Report on Form 8-K, including the exhibits attached hereto, is being furnished and shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/145761...017x8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/145761...-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
(END) Dow Jones Newswires
July 24, 2017 07:05 ET (11:05 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Genocea Biosciences Files 8K - Regulation FD >GNCA
1 hour 45 minutes ago - DJNF
Genocea Biosciences Inc. (GNCA) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on July 24, 2017.
On July 24, 2017, Genocea Biosciences, Inc. (the "Company"
issued a press release announcing positive clinical results from the Company's planned analysis of data collected twelve months after dosing in its placebo-controlled Phase 2b trial of GEN-003 for the treatment of genital herpes. A copy of the press release, dated July 24, 2017, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. On July 24, 2017, the Company will give a presentation to investors regarding the positive clinical results for the twelve-month analysis of the Company's Phase 2b trial of GEN-003 for the treatment of genital herpes. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference. The presentation is also available on the Company's website, www.genocea.com, however the Company's website and any information contained on the website are not incorporated herein.
The information contained in this Item 7.01 of this Current Report on Form 8-K, including the exhibits attached hereto, is being furnished and shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/145761...017x8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/145761...-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
(END) Dow Jones Newswires
July 24, 2017 07:05 ET (11:05 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
